Clinical Trials Browser

Phase 3 × INDUSTRY × HER2-positive Metastatic Breast Cancer × Clear all

NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Phase 3 Unknown

HER2-positive Metastatic Breast Cancer